Towards the same direction, Wang et al. [46] discussed the challenges of using kinase inhibitors to target mutated driving kinases in HCC and provided evidence to demonstrate that co-activation of ALK, FGFR2, and EPHA5 serves as core kinases in HCC cells and their co-activation is required for cell growth. Here, FGFR2 is linked to hepatocellular carcinoma.